(WT+EV and PTTG12/2 +EV), and PTTG1 re-introduced PTTG12/2 (PTTG12/2 +PTTG1) cells were plated in 96-well plates for 24 hours and treated with control vehicle (C) or different doxorubicin doses for another 48 hours. DNA synthesis was assessed by measuring BrdU incorporation. (TIF) Figure S2 HCT116 cells were transfected with pEGFP-N1 plasmids and positive cells counted. Transfection efficiency was calculated by using the formula: number of EGFP-positive cells/ Total cell number*100%. (TIF) References 1. Pei L, Melmed S (1997) Isolation and characterization of a pituitary tumor- transforming gene (PTTG). Mol Endocrinol 11: 433–441. 2. Vlotides G, Eigler T, Melmed S (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28: 165–186. 3. Ogbagabriel S, Fernando M, Waldman FM, Bose S, Heaney AP (2005) Securin is overexpressed in breast cancer. Mod Pathol 18: 985–990. 4. Thompson AD, 3rd, Kakar SS (2005) Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells. FEBS Lett 579: 3195–3200. 5. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M (2004) PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 13: 80–81. 6. Hlubek F, Pfeiffer S, Budczies J, Spaderna S, Jung A, et al. (2006) Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. Br J Cancer 94: 1672–1677. 7. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, et al. (2000) Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 355: 716–719. 8. Sanchez-Puig N, Veprintsev DB, Fersht AR (2005) Human full-length Securin is a natively unfolded protein. Protein Sci 14: 1410–1418. 9. Tong Y, Tan Y, Zhou C, Melmed S (2007) Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 26: 5596–5605. 10. Tong Y, Ben-Shlomo A, Zhou C, Wawrowsky K, Melmed S (2008) Pituitary tumor transforming gene 1 regulates Aurora kinase A activity. Oncogene 27: 6385–6395. 11. Zou H, McGarry TJ, Bernal T, Kirschner MW (1999) Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285: 418–422. 12. Waizenegger I, Gimenez-Abian JF, Wernic D, Peters JM (2002) Regulation of human separase by securin binding and autocleavage. Curr Biol 12: 1368–1378. 13. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, et al. (1999) Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 13: 156–166. 14. Yu R, Ren SG, Horwitz GA, Wang Z, Melmed S (2000) Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol 14: 1137–1146. 15. Pei L (2001) Identification of c-myc as a down-stream target for pituitary tumor- transforming gene. J Biol Chem 276: 8484–8491. 16. Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, et al. (2002) Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 32: 306–311. 17. Yu R, Heaney AP, Lu W, Chen J, Melmed S (2000) Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem 275: 36502–36505. 18. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, et al. (2006) Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology 147: 4781–4791. 19. Abbud RA, Takumi I, Barker EM, Ren SG, Chen DY, et al. (2005) Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol 19: 1383–1391. 20. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S (2005) Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol 19: 2371–2379. 21. Solbach C, Roller M, Eckerdt F, Peters S, Knecht R (2006) Pituitary tumor- transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck. BMC Cancer 6: 242. 22. Ghayad SE, Vendrell JA, Bieche I, Spyratos F, Dumontet C, et al. (2009) Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol 42: 87–103. PTTG1 and Drug-Induced Senescence Acknowledgments PTTG1 WT and KO, P53 WT and KO HCT116 cells were kindly provided by Dr. Bert Vogelstein, Johns Hopkins University. p21-luc and p21-luc Dp53 plasmids were kindly provided by Daiqing Liao, University of Florida College of Medicine. PTTG1-GFP and PTTG1-pcDNA3.1 plasmids were kindly provided by Dr. Run Yu. We thank Dr. Hidenori Fukuoka for his assistance with frozen sections. Author Contributions Conceived and designed the experiments: YT SM. Performed the experiments: YT WZ CZ. Analyzed the data: YT WZ CZ KW. Contributed reagents/materials/analysis tools: YT WZ CZ. Wrote the paper: YT SM. 23. Genkai N, Homma J, Sano M, Tanaka R, Yamanaka R (2006) Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep 15: 1569–1574. 24. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, et al. (2006) Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 43: 1267–1275. 25. Saez C, Martinez-Brocca MA, Castilla C, Soto A, Navarro E, et al. (2006) Prognostic significance of human pituitary tumor-transforming gene immuno- histochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab 91: 1404–1409. 26. Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, et al. (2002) Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol 32: 233–237. 27. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, et al. (2007) Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res 67: 10564–10572. 28. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497–1501. 29. Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, et al. (2001) Securin is required for chromosomal stability in human cells. Cell 105: 445–457. 30. Imaizumi M, Kondo T, Taguchi T, Hattori T, Abe O, et al. (1993) A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors. Surg Today 23: 412–419. 31. Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, et al. (1992) Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 52: 5693–5700. 32. Rebbaa A, Zheng X, Chou PM, Mirkin BL (2003) Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 22: 2805–2811. 33. Mai A, Massa S, Rotili D, Cerbara I, Valente S, et al. (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25: 261–309. 34. Place RF, Noonan EJ, Giardina C (2005) HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol 6: 37. 35. Rebbaa A, Zheng X, Chu F, Mirkin BL (2006) The role of histone acetylation versus DNA damage in drug-induced senescence and apoptosis. Cell Death Differ 13: 1960–1967. 36. Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES (2003) Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol Cell Biol 23: 7719–7731. 37. Gartel AL, Tyner AL (1999) Transcriptional regulation of the p21((WAF1/ CIP1)) gene. Exp Cell Res 246: 280–289. 38. Lu S, Jenster G, Epner DE (2000) Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 14: 753–760. 39. Xiao H, Hasegawa T, Isobe K (2000) p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275: 1371–1376. 40. Billon N, Carlisi D, Datto MB, van Grunsven LA, Watt A, et al. (1999) Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/ CIP1 during NGF-mediated neuronal differentiation. Oncogene 18: 2872–2882. 41. Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, et al. (1999) Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann N Y Acad Sci 886: 195–199. 42. Shay JW, Roninson IB (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23: 2919–2933. 43. Mooi WJ, Peeper DS (2006) Oncogene-induced cell senescence–halting on the road to cancer. N Engl J Med 355: 1037–1046. 44. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, et al. (2007) A dominant role for p53-dependent cellular senescence in radiosensiti- zation of human prostate cancer cells. Cell Cycle 6: 595–605. PLoS ONE | www.plosone.org 12 August 2011 | Volume 6 | Issue 8 | e23754